Champions Oncology posts 8.8% revenue growth and wider margins in fiscal Q1 2027

Champions Oncology reported financial results for its first quarter of fiscal 2027, ended July 31, 2026, in a release dated September 10, 2026. Revenue came to $15.2 million, an increase of 8.8% year over year, with oncology services margin at 51% compared with 43% in the prior-year period, and adjusted EBITDA of $671,000 compared with $59,000 a year earlier.¹

Total oncology revenue rose 8.8% to $15.2 million from $14.0 million in the prior-year period, driven mainly by higher core research services revenue from improved conversion of contracted work into revenue, along with increased data license revenue.¹ Cost of oncology revenue fell to $7.5 million, a decrease of $461,000 or 5.8%, and oncology services margin improved to 51% from 43%, reflecting higher revenue and lower third-party radiolabeling costs.¹

Operating expenses rose as the company expanded its commercial footprint. Sales and marketing expense increased 66.6% to $3.1 million from $1.9 million in the prior-year period, reflecting the company's stated investment in expanding its commercial organization to support growth in both research services and data licensing.¹ Research and development expense rose 12.6% to $2.3 million, primarily due to higher share-based compensation tied to Corellia, the company's wholly owned subsidiary focused on target discovery.¹

Champions reported a net loss of $426,000 for the quarter, compared with a net loss of $466,000 in the prior-year period.¹ Net cash used in operating activities was approximately $492,000, driven primarily by normal working capital movements, and the company ended the quarter with approximately $4.4 million of cash and no debt.¹

Full details of the results will be available on or before September 14, 2026 in the company's Form 10-Q.¹ Champions hosted a conference call the same day, September 10, 2026, at 4:30 p.m. EDT to discuss the results, according to the release.